<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Calcium Chloride</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01164</strong>&#160; (APRD00840)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01164/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01164/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01164.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01164.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01164.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01164.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01164.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01164">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Calcium chloride dihydrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000772/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000772/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: LLSDKQJKOVVTOJ-UHFFFAOYSA-L</li>
              <li>Monoisotopic Mass: 145.921425941</li>
              <li>Average Mass: 147.015</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000772">DBSALT000772</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Jarcal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>LiquiCal-D 400</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Artisial</td><td>Calcium Chloride + Magnesium Chloride + Potassium Chloride + Potassium Phosphate Dibasic + Potassium Phosphate Monobasic + Sodium Chloride</td></tr><tr><td>Electrolyte Infusion</td><td>Calcium Chloride + Dextrose + Magnesium Chloride + Potassium Acetate + Sodium Acetate + Sodium Chloride + Sodium Citrate</td></tr><tr><td>Electrolytes Concentrate</td><td>Calcium Chloride + Dextrose + Magnesium Chloride + Potassium Acetate + Sodium Acetate + Sodium Chloride</td></tr><tr><td>Electromix</td><td>Calcium Chloride + Magnesium Chloride + Potassium Chloride + Sodium Chloride</td></tr><tr><td>Electrosul</td><td>Calcium Chloride + Calcium D-Pantothenate + Cobalt Sulfate + Copper Sulfate + Ferrous Sulfate + Magnesium Sulfate + Manganese Sulfate + Nicotinic Acid + Potassium Chloride + Sodium Chloride + Sulfamerazine Sodium + Sulfathiazole Sodium + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Zinc Sulfate</td></tr><tr><td>Haemosol H-404</td><td>Acetic Acid + Calcium Chloride + Dextrose + Magnesium Chloride + Potassium Chloride + Sodium Chloride</td></tr><tr><td>Inpersol with 1.5% Dextrose</td><td>Calcium Chloride + Dextrose + Magnesium Chloride + Sodium Chloride + Sodium Lactate</td></tr><tr><td>Inpersol with 2.5% Dextrose</td><td>Calcium Chloride + Dextrose + Magnesium Chloride + Sodium Chloride + Sodium Lactate</td></tr><tr><td>Inpersol with 4.25% Dextrose</td><td>Calcium Chloride + Dextrose + Magnesium Chloride + Sodium Chloride + Sodium Lactate</td></tr><tr><td>Iocare Balanced Salt Solution</td><td>Calcium Chloride + Magnesium Chloride + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Citrate</td></tr><tr><td>Lactated Ringer's Injection USP</td><td>Calcium Chloride + Potassium Chloride + Sodium Chloride + Sodium Lactate</td></tr><tr><td>Lactated Ringers Injection</td><td>Calcium Chloride + Potassium Chloride + Sodium Chloride + Sodium Lactate</td></tr><tr><td>Medi-3-Sulvita</td><td>Calcium Chloride + D-Pantothenic Acid + Magnesium Sulfate + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sulfamerazine Sodium + Sulfamethazine Sodium + Sulfathiazole Sodium + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3</td></tr><tr><td>Medilytes Liquid</td><td>Calcium Chloride + Dextrose + Magnesium Chloride + Potassium Acetate + Sodium Acetate + Sodium Chloride</td></tr><tr><td>Moi-Stir Oral Swabsticks</td><td>Calcium Chloride + Magnesium Chloride + Potassium Chloride + Sodium Chloride + Sodium Phosphate Dibasic</td></tr><tr><td>Moi-Stir Spray</td><td>Calcium Chloride + Magnesium Chloride + Potassium Chloride + Sodium Chloride + Sodium Phosphate Dibasic</td></tr><tr><td>Neopaste</td><td>Aluminum Hydroxide + Calcium Chloride + Magnesium Chloride + Neomycin (Neomycin Sulfate) + Potassium Acetate + Sodium Acetate + Sodium Chloride + Sulfamethazine + Sulfathiazole</td></tr><tr><td>Pro-Lyte</td><td>Calcium Chloride + Calcium D-Pantothenate + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Potassium Citrate + Potassium Phosphate Monobasic + Sodium Chloride + Sodium Phosphate Monobasic + Vitamin C</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/supplements">Supplements</a></li></ul></td></tr><tr><th>CAS number</th><td>14639-81-7</td></tr><tr><th>Weight</th><td>Average: 110.984<br>Monoisotopic: 109.900296569</td></tr><tr><th>Chemical Formula</th><td>CaCl<sub>2</sub></td></tr><tr><th>InChI Key</th><td>UXVMQQNJUSDDNG-UHFFFAOYSA-L</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/Ca.2ClH/h;2*1H/q+2;;/p-2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">calcium dichloride</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[Cl-].[Cl-].[Ca++]</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Inorganic Compounds</td></tr><tr><th>Superclass</th><td>Mixed Metal/Non-metal Compounds</td></tr><tr><th>Class</th><td>Alkaline Earth Metal Salts</td></tr><tr><th>Subclass</th><td>Alkaline Earth Metal Chlorides</td></tr><tr><th>Direct parent</th><td>Alkaline Earth Metal Chlorides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td>This compound belongs to the alkaline earth metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a lanthanide.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, for the treatment of magnesium intoxication due to overdosage of magnesium sulfate, and used to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid.</td></tr><tr><th>Pharmacodynamics</th><td>Calcium is the fifth most abundant element in the body and the major fraction is in the bony structure. Calcium plays important physiological roles, many of which are poorly understood. It is essential for the functional integrity of the nervous and muscular systems. It is necessary for normal cardiac function and is one of the factors that operates in the mechanisms involved in the coagulation of blood.</td></tr><tr><th>Mechanism of action</th><td>Calcium chloride in water dissociates to provide calcium (Ca<sup>2+</sup>) and chloride (Cl<sup>-</sup>) ions. They are normal constituents of the body fluids and are dependent on various physiological mechanisms for maintenance of balance between intake and output. For hyperkalemia, the influx of calcium helps restore the normal gradient between threshold potential and resting membrane potential.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.</p></td></tr><tr><th>Route of elimination</th><td>Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.</td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Too rapid injection may produce lowering of blood pressure and cardiac syncope. Persistent hypercalcemia from overdosage of calcium is unlikely because of rapid excretion.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9445</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.975</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6764</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.9039</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9891</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9866</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9196</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8116</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.717</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7571</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7506</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8587</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9306</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8304</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.956</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9002</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6808
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Carcinogens  
        </td>
        <td>
            0.764
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6815
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9786 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9433
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9634
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hospira inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.jtbaker.com">J T Baker</a></li>
<li><a href="http://www.luitpold.com">Luitpold Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Solution / drops</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00630">Alendronate</a></td><td>Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate. </td></tr><tr><td><a href="/drugs/DB00258">Calcium Acetate</a></td><td>Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. </td></tr><tr><td><a href="/drugs/DB06724">Calcium carbonate</a></td><td>Calcium salts may enhance the adverse/toxic effect of calcium chloride. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. </td></tr><tr><td><a href="/drugs/DB01212">Ceftriaxone</a></td><td>Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. </td></tr><tr><td><a href="/drugs/DB00720">Clodronate</a></td><td>Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.</td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as demeclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. </td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours. </td></tr><tr><td><a href="/drugs/DB01077">Etidronic acid</a></td><td>Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.</td></tr><tr><td><a href="/drugs/DB00710">Ibandronate</a></td><td>Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.</td></tr><tr><td><a href="/drugs/DB00451">Levothyroxine</a></td><td>Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB00279">Liothyronine</a></td><td>Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. </td></tr><tr><td><a href="/drugs/DB00884">Risedronate</a></td><td>Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate. </td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. </td></tr><tr><td><a href="/drugs/DB01133">Tiludronate</a></td><td>Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.</td></tr><tr><td><a href="/drugs/DB06824">Trientine hydrochloride</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk. </td></tr><tr><td><a href="/drugs/DB00685">Trovafloxacin</a></td><td>Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>